Human papillomaviruses and cancer in Uganda

Abstract

In a case-control study in Uganda, we examined associations between different cancer sites or types in relation to antibodies against human papillomaviruses (HPV)-16, -18 and -45. For each cancer site or type, the control group comprised all other cancers excluding those known, or thought to be associated with HPV infection (cancers of the uterine cervix, penis and eye). Among controls the seroprevalence of antibodies was 11% (68/616) against HPV-16, 5% (29/605) against HPV-18 and 6% (35/605) against HPV-45. Antibodies against HPV-16 were significantly associated with only two cancers: uterine cervix [prevalence of antibodies 27% (51/191); odds ratio (OR) 2.0, 95% confidence interval (CI) 1.2-3.1, P=0.01] and penis [prevalence of antibodies 27% (4/15); OR 6.4, 95% CI 1.7-24.3, P=0.01]. For both cancers, the risk increased with increasing anti-HPV-16 antibody titre (Ptrend=0.01 for each). No cancer site or type was significantly associated with antibodies against HPV-18 and -45.

Cervical Human Papillomavirus (HPV) Infection and HPV Type 16 Antibodies in South African Women

“…Notably, though, transient HPV infections do not elicit seroconversion, and some women with persistent infection fail to seroconvert (5). Within Africa, a Ugandan study found HPV-16 antibodies significantly associated with cancer of the cervix (20). The present study constituted the first assessment in southern Africa, and possibly the rest of Africa, of cervical HPV infection, as well as HPV-16 antibody prevalence and associated risk factors, in a large population (Ͼ1,000).…”

Human papillomavirus prevalence and type distribution in penile carcinoma

“…A careful correlation of these mixtures and the presence of HPV are also necessary to weight the role of these neoplasms in the viral pathway of carcinogenesis. Associated studies using HPV serology markers support a strong relationship between HPV and SCC penile cancer, with odds ratios ranging from 1.7 to 6.4 12 37 44 54 55…”

Human Papillomavirus (HPV) Infection: Molecular Epidemiology, Genotyping, Seroprevalence and Associated Risk Factors among Arab Women in Qatar

“…Additionally, it has been shown that the cell-mediated immune response cleared the majority of HPV infections within 1–2 year’s exposure [14]. Despite the fact that a number of seroprevalence studies have been conducted in resource-rich countries and some in resource-poor countries [15–18], no such data appears to be available from the Arab world.…”